Thank you to Madrigal for sponsoring this FAQ Video Module.
In this GHAPP FAQ Video Module, Corrie Berk, NP, Director of Hepatology and Transplant Outreach Programs at the Texas Liver Institute, shares insights on the consequences of untreated metabolic-associated steatohepatitis (MASH) and the importance of early intervention. She discusses how MASH can silently progress to liver failure, liver cancer, and increase cardiovascular risks. Corrie provides valuable strategies for advanced practice providers (APPs) to educate patients, focusing on simplifying complex information, promoting lifestyle changes, and emphasizing the benefits of early intervention.
Related Podcast

Part 3 - Strategies for Educating the APP Community on MASH
2024

Part 2 - Using NITs to Identify and Manage MASH Patients
2024

What Is Resmetirom and How Does It Work to Treat MASH?
2025

Key Takeaways - Major Advancements In The Management of MASH with Parvez, Mantry, MD
2024

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
2025

What Is the Clinical Profile of Resmetirom, Including Dosing Schedules?
2025

How Is MASH Severity Staged? What Would an Ideal MASH NIT Algorithm Look Like?
2025

GHAPPcast: Recognizing the Severity of MASH
2025

What is MASH?
2025

Part 1 - Incorporating the Newly Approved Therapy for MASH into Practice
2024